On average, research analysts predict that ACADIA Pharmaceuticals will post -1.In 2019, the NSW Department of Planning, Industry and Environment prepared a Master Plan for the Parkes, Wagga Wagga Special Activation Precincts (SAPs) and the Go Jindabyne Master Plan. During the same quarter last year, the company posted ($0.27) EPS. The company's quarterly revenue was up 16.8% compared to the same quarter last year. ACADIA Pharmaceuticals had a negative net margin of 39.93% and a negative return on equity of 41.18%. The firm had revenue of $134.56 million during the quarter, compared to analysts' expectations of $130.06 million. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.04. The firm has a 50-day moving average price of $15.98 and a two-hundred day moving average price of $18.76.ĪCADIA Pharmaceuticals ( NASDAQ:ACAD - Get Rating) last posted its quarterly earnings data on Monday, August 8th. ACADIA Pharmaceuticals has a 1-year low of $12.24 and a 1-year high of $28.06. The stock has a market capitalization of $2.90 billion, a PE ratio of -14.10 and a beta of 0.67. ACADIA Pharmaceuticals Trading Up 3.0 %ĪCAD opened at $17.91 on Tuesday.
Based on data from, the company currently has an average rating of "Hold" and an average price target of $22.72. One analyst has rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the company. Finally, Royal Bank of Canada lowered their price target on shares of ACADIA Pharmaceuticals from $26.00 to $21.00 and set an "outperform" rating for the company in a research report on Tuesday, August 9th. Mizuho lowered their price target on shares of ACADIA Pharmaceuticals from $27.00 to $19.00 and set a "neutral" rating for the company in a research report on Tuesday, August 9th. cut shares of ACADIA Pharmaceuticals from an "overweight" rating to a "neutral" rating in a research report on Tuesday, June 21st. HC Wainwright lifted their price target on shares of ACADIA Pharmaceuticals from $20.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, August 9th. Jefferies Financial Group cut shares of ACADIA Pharmaceuticals from a "buy" rating to an "underperform" rating and lowered their price target for the stock from $25.00 to $10.00 in a research report on Tuesday, June 21st. Several other brokerages have also recently commented on ACAD.
7 Sports Betting Stocks to Buy for Their Long-Term Possibilities.7 Water Stocks to Buy as the World Dries Up.7 Solar Stocks Leading the Clean Energy Boom.7 Railroad Stocks to Keep Your Portfolio Chugging Along.7 Agricultural Stocks to Buy to Keep Your Portfolio Well Fed.
#Victoria 2 stockpile buy sell cracker
0 kommentar(er)
